Biogen Stock Quote Today


USD 285.37  3.73  1.29%   

Market Performance
8 of 100
Odds Of Distress
Less than 9
Biogen is trading at 285.37 as of the 10th of December 2022, a -1.29 percent decrease since the beginning of the trading day. The stock's open price was 289.1. Biogen has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Biogen Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 10th of November 2022 and ending today, the 10th of December 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
16th of September 1991
Health Care
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. Biogen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 144 M outstanding shares of which 2.43 M shares are currently shorted by private and institutional investors with about 1.68 trading days to cover. More on Biogen Inc

Moving against Biogen

-0.77EDITEditas Medicine Downward RallyPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Biogen Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Biogen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Biogen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Biogen Inc is way too risky over 90 days horizon
Biogen Inc appears to be risky and price may revert if volatility continues
Biogen Inc has a strong financial position based on the latest SEC filings
Over 88.0% of the company shares are held by institutions such as insurance companies
Latest headline from Atlantic Equities Adjusts Price Target on Biogen to 295 From 220, Maintains Neutral Rating -
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Biogen's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Biogen's managers, analysts, and investors.
Environment Score
Governance Score
Social Score
CEO and DirectorGeorge Scangos
Thematic IdeaDrugs (view all)
Excise Tax ActivitiesAnimal Testing
Fama & French Classification
Average Analyst Recommendation
Analysts covering Biogen report their recommendations after researching Biogen's financial statements, talking to executives and customers, or listening in on Biogen's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Biogen Inc. The Biogen consensus assessment is calculated by taking the average forecast from all of the analysts covering Biogen.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Biogen Inc based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Biogen Inc financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted203.3 M149.6 M
Significantly Up
Slightly volatile
Weighted Average Shares202.4 M149.1 M
Significantly Up
Slightly volatile
Return on Average Assets6.596.4174
Fairly Up
Net Cash Flow from Operations3.5 B3.6 B
Sufficiently Down
Slightly volatile
Current Liabilities3.4 B4.3 B
Significantly Down
Slightly volatile
Total Liabilities10.3 B13 B
Significantly Down
Slightly volatile
Gross Margin93.280.7889
Fairly Up
Slightly volatile
Total Debt6.6 B7.6 B
Fairly Down
Slightly volatile
Asset Turnover0.570.4529
Significantly Up
Slightly volatile
Current Assets6.6 B7.9 B
Fairly Down
Slightly volatile
Total Assets20.3 B23.9 B
Fairly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Biogen's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Biogen's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Biogen's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Biogen's bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Biogen's outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biogen's financial leverage. It provides some insight into what part of Biogen's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Biogen's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Biogen deploys its capital and how much of that capital is borrowed.
Biogen cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 6.27 B in liabilities with Debt to Equity (D/E) ratio of 0.52, which is about average as compared to similar companies. Biogen Inc has a current ratio of 2.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Biogen until it has trouble settling it off, either with new capital or with free cash flow. So, Biogen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biogen Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biogen to invest in growth at high rates of return. When we think about Biogen's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

3.48 Billion
Biogen Inc (BIIB) is traded on NASDAQ Exchange in USA and employs 9,610 people. Biogen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 41.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Biogen's market, we take the total number of its shares issued and multiply it by Biogen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Biogen Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 144 M outstanding shares of which 2.43 M shares are currently shorted by private and institutional investors with about 1.68 trading days to cover. Biogen Inc currently holds about 4.91 B in cash with 3.64 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 34.1.
Check Biogen Probability Of Bankruptcy
Biogen holds a total of one hundred fourty-four million nine hundred ninety-two outstanding shares. The majority of Biogen Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Biogen Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Biogen. Please pay attention to any change in the institutional holdings of Biogen Inc as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Biogen Ownership Details

Biogen Stock Price Odds Analysis

What are Biogen's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Biogen jumping above the current price in 90 days from now is about 27.29%. The Biogen Inc probability density function shows the probability of Biogen stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4038 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Biogen will likely underperform. Additionally, the company has an alpha of 0.5777, implying that it can generate a 0.58 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 285.37HorizonTargetOdds Above 285.37
72.60%90 days
Based on a normal probability distribution, the odds of Biogen to move above the current price in 90 days from now is about 27.29 (This Biogen Inc probability density function shows the probability of Biogen Stock to fall within a particular range of prices over 90 days) .

Biogen Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Biogen that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Biogen's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biogen's value.
InstituionSecurity TypeTotal SharesValue
Zwj Investment Counsel IncCommon Shares1.4 K457 K
Zwj Investment Counsel IncCommon Shares1.3 K408 K
View Biogen Diagnostics

Biogen Historical Income Statement

Biogen Inc Income Statement is one of the three primary financial statements used for reporting Biogen's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Biogen Inc revenue and expense. Biogen Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Biogen Direct Expenses is projected to increase significantly based on the last few years of reporting. The past year's Direct Expenses was at 2.11 Billion. The current year Consolidated Income is expected to grow to about 2.7 B, whereas Cost of Revenue is forecasted to decline to about 1.9 B. View More Fundamentals

Biogen Stock Against Markets

Picking the right benchmark for Biogen stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Biogen stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Biogen is critical whether you are bullish or bearish towards Biogen Inc at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Biogen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now


Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Biogen Corporate Directors

Biogen corporate directors refer to members of a Biogen board of directors. The board of directors generally takes responsibility for the Biogen's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Biogen's board members must vote for the resolution. The Biogen board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Jesus Mantas - DirectorProfile
Richard Mulligan - Independent DirectorProfile
Alexander Denner - Independent DirectorProfile
Eric Rowinsky - Independent DirectorProfile

Invested in Biogen Inc?

The danger of trading Biogen Inc is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Biogen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Biogen. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Biogen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for analysis

When running Biogen Inc price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
41.6 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine Biogen value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.